S&P 500 Healthcare Sector SEC Filings — April 02, 2026

02-04-2026

Lamar Advertising Co/New (LAMR) DEF 14A proxy statement for the virtual annual meeting on May 14, 2026 (record date March 16, 2026) outlines voting on director elections, ratification of KPMG LLP as auditor, advisory approval of NEO compensation, and amendments to the 1996 Equity Incentive Plan and 2019 Employee Stock Purchase Plan. Outstanding shares as of record date: 87,021,456 Class A (1 vote/share), 14,420,085 Class B (10 votes/share), and 5,719.49 Series AA Preferred (1 vote/share), with quorum at one-third. The Reilly family maintains significant control via Class B shares, including Kevin P. Reilly Jr. (78.79% of Class B), Sean E. Reilly (73.22%), and Reilly Family LLC (62.41%), alongside 5% Class A holders Vanguard Group (14.53%) and BlackRock Inc. (10.39%).

• ·Quorum requires holders of one-third of voting shares.
• ·Broker non-votes and abstentions count for quorum but not votes cast.
• ·Voting deadlines: internet/telephone by 11:59 p.m. CDT May 13, 2026; questions by 10:59 p.m. CDT May 11, 2026.
• ·Class B and Series AA holders receive printed materials; Class A via notice.
• ·Proxy default vote: FOR all proposals.

02-04-2026

Manhattan Associates, Inc. filed its DEF 14A proxy statement for the 2026 Annual Meeting of Shareholders on May 14, 2026, seeking approval for election of three Class I directors (expiring 2029), advisory vote on named executive officer compensation, ratification of Ernst & Young LLP as independent auditors for FY 2026, and the First Amendment to the 2020 Equity Incentive Plan. The proxy highlights 2025 business progress, including $145 million in R&D investment (up 5% YoY) focused on Manhattan Active® cloud solutions and new AI-driven products like Manhattan Active® Agents, while noting risks outlined in the 2025 Form 10-K. The Board consists of 8 directors (75% independent) with active committees holding 5 full board, 4 audit, 6 compensation, and 4 nomination/governance meetings in FY 2025.

• ·Record date: March 18, 2026
• ·Meeting location: 2300 Windy Ridge Parkway, Atlanta, GA 30339 at 9:00 a.m. ET
• ·Proposal 1 voting: Plurality, with majority withhold policy requiring resignation offer
• ·Proposals 2, 3, 4 voting: Majority of votes cast in favor vs. against
• ·2025 Annual Report on Form 10-K available at www.manh.com Investor Relations

02-04-2026

Caris Life Sciences, Inc. entered into a new senior secured Financing Agreement on April 1, 2026, providing a $400,000,000 initial term loan (funded at closing), up to $300,000,000 delayed draw term loan facility (available through August 2027 for permitted acquisitions), and an uncommitted $500,000,000 incremental facility, with lenders including funds managed by Blue Owl Capital and Blackstone. Proceeds from the initial term loan fully repaid and terminated the prior credit agreement dated January 18, 2023. The new facility matures in April 2031, carries interest margins of Term SOFR + 5.00% or Base Rate + 4.00%, and requires maintenance of at least $50,000,000 in minimum qualified cash quarterly.

• ·Obligations guaranteed by certain subsidiaries and secured on a first-priority basis by substantially all tangible and intangible personal property, including pledges of subsidiary capital stock.
• ·New Credit Agreement contains customary covenants limiting debt incurrence, liens, investments, asset dispositions, affiliate transactions, and prepayments of certain indebtedness.
• ·Events of default include payment failures, covenant breaches, bankruptcy, and change of control, allowing lender acceleration.

02-04-2026

News Corporation filed an 8-K on April 2, 2026, disclosing information provided to the Australian Securities Exchange (ASX) regarding its ongoing $1 billion stock repurchase program for Class A (NWSA) and Class B (NWS) common stock, as required under ASX rules. Exhibits 99.1 and 99.2 contain the specific ASX disclosures dated as noted therein. The filing includes forward-looking statements on potential repurchases, subject to market conditions and other factors.

• ·Event date (earliest reported): April 1, 2026
• ·Securities registered: Class A Common Stock (NWSA, par value $0.01/share, Nasdaq Global Select Market); Class B Common Stock (NWS, par value $0.01/share, Nasdaq Global Select Market)

02-04-2026

CareView Communications, Inc., along with its subsidiary Borrower, PDL Investment Holdings, LLC as Lender, Steven G. Johnson (President and CEO), and Dr. James R. Higgins (director), entered into the Fourteenth Amendment to the Credit Agreement on March 30, 2026, extending the Maturity Date to June 30, 2026. This amendment continues a long series of prior modifications to the original June 26, 2015 Credit Agreement and related Modification Agreement, with dozens of amendments listed dating back to 2015. The update creates or modifies a direct financial obligation under Item 2.03.

• ·Original Credit Agreement dated June 26, 2015
• ·Filing incorporates 30+ prior amendments to Credit Agreement and Modification Agreement as exhibits, with latest prior ones in December 2025

02-04-2026

Sally Beauty Holdings, Inc. (NYSE: SBH) appointed Adrianne Lee as Senior Vice President and Chief Financial Officer effective April 28, 2026, succeeding Marlo Cormier, who will depart effective April 11, 2026, to pursue other opportunities. Ms. Lee brings extensive finance leadership experience from Bed Bath & Beyond, The Hertz Corporation, and other firms. The Company reaffirmed its previously issued second quarter and fiscal year 2026 financial guidance.

• ·Adrianne Lee previously served as President and CFO at Bed Bath & Beyond, joining as CFO in 2020
• ·Guidance for Q2 and FY2026 originally provided on February 9, 2026
• ·Sally Beauty operates through Sally Beauty and Beauty Systems Group segments

02-04-2026

Roivant announced expansion of the brepocitinib program with a seamless Phase 2b/3 trial in lichen planopilaris (LPP), enrolling first subjects in March 2026 as the fourth late-stage indication alongside dermatomyositis (DM; PDUFA Q3 2026), non-infectious uveitis (NIU), and cutaneous sarcoidosis (CS). However, Immunovant’s two Phase 3 studies of batoclimab in thyroid eye disease (TED) failed to meet the primary endpoint of ≥2mm proptosis responder rate at Week 24, despite greater proptosis improvements during the initial high-dose period. Roivant will host an investor call on April 2, 2026, at 8:00 a.m. ET, and Immunovant plans to advance IMVT-1402, with Graves’ disease topline data expected in 2027.

• ·No FDA-approved therapies exist for LPP.
• ·FDA granted Priority Review to brepocitinib NDA for DM with PDUFA target action date in Q3 2026.
• ·Topline Phase 3 data in NIU expected in H2 2026.
• ·Phase 3 study initiation in CS expected in H2 2026.
• ·Topline data from IMVT-1402 studies in Graves’ disease expected in 2027.
• ·Safety results for batoclimab in TED consistent with previous findings, no new safety signals.

02-04-2026

Oportun Financial Corporation announced that Kate Layton (Chief Legal Officer and Corporate Secretary) and Gaurav Rana (General Manager of Lending) will jointly lead as interim CEOs effective April 4, 2026, following the previously announced departure of Raul Vazquez as CEO and Board member. Vazquez will serve as an advisor until July 3, 2026, while the Board advances its search for a permanent CEO. Lead Independent Director Louis P. Miramontes highlighted progress in the CEO selection process and praised the interim leaders' deep business knowledge.

• ·Kate Layton joined Oportun in 2015, previously Deputy General Counsel and Corporate Secretary.
• ·Gaurav Rana joined Oportun in 2017 as Head of Data and Analytics.
• ·Investor Contact: Dorian Hare (650) 590-4323, ir@oportun.com

02-04-2026

WSFS Financial Corporation has issued definitive additional proxy materials for its 2026 Annual Meeting of Stockholders, to be held virtually on May 14, 2026 at 4:00 PM Eastern Time. The meeting includes Proposal 1: election of three directors (Eleuthère I. du Pont, Michelle Hong, David G. Turner) for a three-year term ending at the 2029 Annual Meeting; Proposal 2: advisory approval of named executive officers' compensation; and Proposal 3: ratification of KPMG LLP as independent auditors for the fiscal year ending December 31, 2026. The Board recommends voting 'FOR' all proposals, with proxy materials available online at https://web.viewproxy.com/wsfs/2026.

• ·Proxy materials request deadline: May 6, 2026 for timely delivery
• ·Virtual meeting registration deadline: 11:59 PM EDT on May 11, 2026
• ·Voting methods: Internet at www.AALvote.com/WSFS using 11-digit Control Number, prior to or during the meeting

02-04-2026

The 520 Almanor Mortgage Loan, constituting approximately 5.4% of the 3650R 2021-PF1 Commercial Mortgage Trust's asset pool as of its cut-off date, has undergone a special servicer change from CWCapital Asset Management LLC to Torchlight Loan Services, LLC, effective April 2, 2026. This loan is part of a loan combination serviced under the Benchmark 2021-B30 Mortgage Trust's pooling and servicing agreement dated November 1, 2021. The appointment follows Section 3.22(b) of the PSA in the interest of transaction management.

• ·Torchlight Loan Services, LLC principal special servicing office: 90 Park Avenue, 20th Floor, New York, New York 10016; Telephone: 212-883-2800
• ·Change effective as of April 2, 2026, pursuant to Section 3.22(b) of the BMARK 2021-B30 PSA dated November 1, 2021

02-04-2026

On March 27, 2026, Cingulate Inc. appointed Zhanpeng “Frederick” Jiang as a Class I director, effective immediately following stockholder approval of the Issuance Proposal, to serve until the 2028 Annual Meeting. Mr. Jiang, determined to be independent, was also appointed to the Audit, Compensation, and Nominating and Corporate Governance Committees. He was granted an option to purchase 15,000 shares of common stock and annual cash retainers of $40,000 for Board service plus $7,500, $5,000, and $4,000 for committee services.

• ·Mr. Jiang's stock option has an exercise price equal to the last reported sale price on Nasdaq on grant date and vests in two equal installments over one year.
• ·Filing references prior Form 8-K dated January 28, 2026, for securities purchase agreement details.
• ·Company is an emerging growth company under Rule 405/12b-2.

02-04-2026

Vertex Pharmaceuticals Incorporated (VRTX) filed a DEFA14A Definitive Additional Materials proxy statement with the SEC on April 02, 2026. The filing is soliciting material under §240.14a-12, submitted by the registrant with no fee required. No substantive financial or operational details are provided in the filing header.

02-04-2026

Riverview Bancorp, Inc. (NASDAQ: RVSB) appointed Kourosh Zamani and Jon Girod to its Board of Directors for Riverview Bank and Riverview Bancorp, effective immediately on April 2, 2026. Zamani, co-founder of AI technology firm Laurel (raised over $150M), and Girod, owner of Quail Homes who built over 3,000 homes and developed more than 2,000 lots, bring expertise in technology, business development, and community real estate. The company reports $1.51B in assets as of December 31, 2025, with 17 branches focused on community banking.

• ·Riverview Bank is 103 years old.
• ·Named Best Bank by readers of The Columbian for the past 12 years.
• ·Headquartered in Vancouver, WA, with focus on commercial, business, and retail clients.

02-04-2026

On April 1, 2026, the Board of Directors of Tyra Biosciences, Inc. designated Julia Rueb, Vice President, Finance, as the company's principal accounting officer, succeeding Alan Fuhrman in that role. Mr. Fuhrman continues to serve as the principal financial officer and Chief Financial Officer. This is a routine internal designation with no reported changes to executive leadership structure.

• ·Ms. Rueb, 40, has served as VP Finance since January 2024, previously Director/Senior Director of Accounting and Corporate Controller (Oct 2022-Dec 2023).
• ·Ms. Rueb holds a Master’s degree in Accounting from the University of San Diego and is a Certified Public Accountant.
• ·Ms. Rueb has no family relationships with any of the company’s directors or executive officers.
• ·Common Stock (TYRA) trades on Nasdaq Global Select Market; company is an emerging growth company.

02-04-2026

TFS Financial Corporation's primary subsidiary, Third Federal Savings & Loan Association of Cleveland, announced the retirement of Meredith S. Weil as Board of Directors member and Chief Financial Officer effective January 2027, following nearly 30 years with the company including roles as COO and Board member since 2014. James E. LaRocca, formerly EVP and CFO of Westfield Bank (acquired by First Financial Bancorp in November 2025), will join as Finance and Accounting Officer on June 29, 2026, and is expected to assume the CFO role. As of December 31, 2025, the company's assets totaled $17.50 billion.

• ·Third Federal founded in 1938 as a mutual association and became part of public company in 2007 (Nasdaq: TFSL)
• ·Ms. Weil served as COO from 2012-2023 and CFO since 2024
• ·Mr. LaRocca held BA in Accounting and MBA from Baldwin-Wallace University; licensed CPA in Ohio

02-04-2026

Nexscient, Inc. appointed Eric Sherb as Chief Financial Officer effective April 1, 2026, via a consulting agreement with EMS Consulting Services, Inc., which includes a $5,000 monthly retainer and a one-time grant of 36,000 common shares vesting over six months. Mr. Sherb, a CPA with 19 years of experience from firms like PricewaterhouseCoopers and prior CFO roles at public companies including Scienture Holdings, Inc., was engaged to provide CFO-level financial and accounting services. The agreement is terminable by either party at any time, with no family relationships or other disclosable transactions involving Mr. Sherb.

• ·Consulting agreement dated March 31, 2026.
• ·Mr. Sherb's experience includes IPOs, SPACs, de-SPACs, debt/equity financings.
• ·No family relationships with directors or officers.
• ·No transactions requiring disclosure under Item 404(a) of Regulation S-K.

02-04-2026

Becton Dickinson reported revenues of $4,486 million for the three months ended December 31, 2025 (Q1 FY2026), up 3.5% YoY from $4,333 million, with GAAP operating income surging 66.0% to $468 million and net income from continuing operations more than doubling to $311 million. However, full FY2025 total net income declined 1.6% YoY to $1,678 million from $1,705 million, driven by a drop in discontinued operations income to $577 million from $651 million, while diluted EPS remained nearly flat at $5.82 versus $5.86. Adjusted non-GAAP diluted EPS from continuing operations for Q1 FY2026 fell 10.1% YoY to $2.50 from $2.78, reflecting ongoing adjustments for purchase accounting, integration, restructuring, and other special items.

• ·Purchase accounting adjustments added $384 million to gross margin in Q1 FY2026.
• ·Integration, restructuring, and transaction expenses totaled $108 million in Q1 FY2026 GAAP results.
• ·Product, litigation, and other items contributed $19 million to operating income adjustments in Q1 FY2026.
• ·FY2025 included $297 million charges related to product liability and certain other legal matters.

02-04-2026

Citigroup Inc. filed its DEF 14A Proxy Statement on April 2, 2026, for the 2026 Annual Meeting on May 20, 2026 (record date March 23, 2026), proposing election of 13 director nominees (85% independent, average tenure 8.7 years), ratification of the independent auditors, advisory approval of 2025 executive compensation, and additional shares for the 2019 Stock Incentive Plan. The Board highlights recent refreshment with 3 new directors elected in the last 5 years; however, 5 nominees have served more than 10 years. All proposals are recommended for approval by the Board.

• ·Annual Meeting: May 20, 2026, 2:00 p.m. ET (virtual at www.virtualshareholdermeeting.com/CITI2026)
• ·Record Date: March 23, 2026
• ·Fiscal Year End: December 31
• ·Compensation disclosures reference periods 2021-2025 for PEO (Jane Fraser, Mike Corbat) and Non-PEO NEOs across components including equity awards, pensions, and fair value changes (no specific values provided)

02-04-2026

Minerva Neurosciences, Inc. (NERV) announced a leadership transition with the appointment of Jim O’Connor as Chief Business Officer and General Counsel effective April 21, 2026, as Geoff Race steps down from his role as President after 16 years but will continue as a consultant. Dr. Remy Luthringer expressed gratitude for Race's foundational contributions and confidence in O’Connor to advance roluperidone through its next Phase 3 trial. O’Connor brings over 20 years of experience, including negotiating >$130 million in financings and FDA regulatory successes.

• ·Jim O’Connor previously served at Axena Health in roles including General Counsel & Chief Operating Officer, General Counsel & Chief Financial Officer, and Interim CEO.
• ·O’Connor oversaw FDA 510(k) clearance, label expansions, and FDA Breakthrough Device Designation via appeal.
• ·Geoff Race joined Minerva in 2010 and held roles including EVP & CFO and Chief Business Officer.
• ·Filing date: April 02, 2026

02-04-2026

Associated Banc-Corp completed its merger with American National Corporation on April 1, 2026, pursuant to a Merger Agreement dated November 30, 2025, resulting in the Board increasing its size from 13 to 14 directors and appointing Wende Kotouc, former Executive Co-Chairman and CEO of American National Bank, as a new director nominee under added Proposal 4 for the April 28, 2026 virtual Annual Meeting. Ms. Kotouc became the beneficial owner of 10,648,000 shares (5.7%) of Associated common stock via a 36.250 exchange ratio, while her husband John F. Kotouc entered a two-year consulting agreement with an annual retainer of $400,000. The supplement provides her background, compensation details including a $400,000 base salary and $1,694,049 severance, and notes she is not independent, leaving nine of 11 nominees independent.

• ·Annual Meeting record date: March 5, 2026; virtual at www.virtualshareholdermeeting.com/ASB2026 on April 28, 2026 at 11:00 a.m. CDT
• ·Transfer restrictions on shares: no transfers first 60 days post-merger; then limited to 150,000 shares per day publicly
• ·Three directors not standing for re-election at Annual Meeting (per original Proxy Statement)
• ·Nine of 11 director nominees are independent

02-04-2026

Peoples Financial Services Corp. appointed Gerard A. Champi as President of Peoples and Peoples Security Bank and Trust Company effective April 3, 2026, succeeding Thomas P. Tulaney who is retiring on the same date; Champi will continue as CEO. Tulaney entered a consulting agreement with Peoples Bank for senior advisory services at $8,000 per month. Director Elisa Zúñiga Ramirez provided notice on April 1, 2026, that she will not stand for reelection at the 2026 annual meeting, with no disagreements cited, leading to board size reductions.

• ·No family relationship between Gerard A. Champi and any other director or executive officer.
• ·Gerard A. Champi not involved in any Item 404(a) disclosable transactions.
• ·Elisa Zúñiga Ramirez's decision to not stand for reelection not due to any disagreement with Peoples.
• ·Consulting agreement terminable by either party with 30 days' written notice.
• ·Peoples accelerated vesting of Tulaney's awards and transferred company-owned vehicle upon retirement.

02-04-2026

On March 31, 2026, the Board of Directors of Jade Biosciences, Inc. approved the 2026 Employment Inducement Stock Incentive Plan, reserving 1,750,000 shares of common stock for issuance. The plan mirrors the 2025 Stock Incentive Plan but restricts awards to new employees per Nasdaq Rule 5635(c)(4), without stockholder approval or incentive stock options. The Company plans to include full plan details in its Form 10-Q for the quarter ended March 31, 2026.

• ·Awards under the plan may only be granted to employees not previously employed by the Company or following a bona fide non-employment period, as an inducement to commence employment.
• ·The Company will file the complete 2026 Inducement Plan and related stock option and restricted stock unit agreements as exhibits to its Q1 2026 Form 10-Q.

02-04-2026

LPL Financial Holdings Inc. issued a DEFA14A proxy statement for its 2026 Annual Meeting of Stockholders on May 14, 2026, at 8:00 AM ET in Fort Mill, SC. Shareholders are voting on electing 11 director nominees (including Edward C. Bernard, H. Paulett Eberhart, and others), ratifying Deloitte & Touche LLP as independent auditors for FY ending December 31, 2026, approving executive compensation on an advisory basis, and adopting Charter amendments to eliminate supermajority voting, add officer exculpation, and remove the corporate opportunities provision.

• ·Materials request deadline: April 30, 2026 via www.ProxyVote.com, 1-800-579-1639, or sendmaterial@proxyvote.com
• ·Meeting address: 1055 LPL Way, Fort Mill, SC 29715
• ·Board recommends 'For' on all proposals

02-04-2026

New Providence Acquisition Corp. III (SPAC) filed a Rule 425 communication on April 2, 2026, disclosing a social media post by Abra Financial Holdings, Inc. regarding their Business Combination Agreement dated March 16, 2026, involving SPAC, Abra, and Aether Merger Sub I, Corp. The filing provides legal disclosures about an upcoming Form S-4 Registration Statement, proxy solicitation for SPAC shareholders, and access to documents via SEC or SPAC's CFO. It emphasizes extensive forward-looking statement risks, including transaction failure, regulatory hurdles in digital assets, high costs, dilution, and operational disruptions, urging investors to review future filings.

• ·SPAC Commission File No.: 001-42610
• ·SPAC address: 401 S County Road #2588, Palm Beach, FL 33480
• ·IPO Prospectus filed with SEC on April 24, 2025
• ·Risks include high redemptions by SPAC public shareholders, potential Nasdaq delisting, and classification as investment company under 1940 Act

02-04-2026

Ares Financial Consulting, LLC filed its 13F-HR on April 2, 2026, disclosing institutional holdings as of March 31, 2026. The portfolio features top positions in Vanguard Total Stock Market ETF valued at $14.28M (44,192 shares), WisdomTree Floating Rate Treasury Fund ETF at $7.90M (156,923 shares), SABA Closed End Funds ETF at $2.53M (110,502 shares), and Amazon.com Inc at $1.11M (5,256 shares), with holdings spanning equities, ETFs, REITs, and ADRs across sectors. No material changes or performance metrics are reported, with most positions showing minor share adjustments of 0-1 shares.

• ·Business address: 4500 Park Granada, Suite 202, Calabasas, CA 91302
• ·CIK: 0002106717
• ·SEC File Number: 028-26022
• ·All reported positions held with sole voting authority

02-04-2026

Abra Financial Holdings, Inc. shared a social media post on April 2, 2026, regarding its Business Combination Agreement dated March 16, 2026, with New Providence Acquisition Corp. III (a SPAC) and Aether Merger Sub I, Corp., announcing intent to file a Form S-4 Registration Statement with the SEC, including a proxy statement/prospectus for shareholder approval of the proposed business combination. The communication provides standard legal disclaimers, directs interested parties to future SEC filings for details, and lists 34 extensive risk factors, including regulatory uncertainties around digital assets, potential transaction failure, dilution, and operational challenges. No financial metrics or performance data are disclosed.

• ·SPAC Commission File No.: 001-42610
• ·SPAC address: 401 S County Road #2588, Palm Beach, FL 33480
• ·SPAC IPO Prospectus filed April 24, 2025

02-04-2026

New Fortress Energy Inc. entered into the LCF Forbearance Agreement on March 27, 2026, with lenders under the Letter of Credit Agreement (dated July 16, 2021), whereby lenders agreed to forbear from exercising rights and remedies on specified defaults until September 15, 2026. The agreement aligns with the Restructuring Support Agreement (RSA) signed on March 17, 2026, to support recapitalization of the company's indebtedness. Without further forbearance post-termination, the company could face requirements to cash collateralize outstanding principal and other obligations under the facility.

• ·Letter of Credit Agreement originally dated July 16, 2021.
• ·8-K filed on April 2, 2026, reporting event of March 27, 2026.
• ·Soliciting material pursuant to Rule 14a-12.

02-04-2026

MFS announced the adjournment of special shareholder meetings for MFS High Income Municipal Trust (CXE) and MFS Investment Grade Municipal Trust (CXH) to April 7, 2026, to solicit additional votes for their reorganizations into MFS Municipal Income Trust (MFM). The boards of the Target Funds approved the Reorganizations on December 10, 2025, and recommend approval, while MFM's board approved a new investment adviser (Aberdeen), five new trustees, and additional share issuance, all ratified by MFM shareholders on April 2, 2026. A conditional tender offer for up to 50% of CXH shares at 99% of NAV is contingent on Reorganization approval.

• ·Target Fund boards unanimously approved Reorganizations on December 10, 2025.
• ·Prospectus/proxy statements mailed to Target Fund shareholders as of December 11, 2025, in early February 2026.
• ·CXH tender offer announced March 4, 2026; commencement contingent on Reorganization vote at adjourned meeting.
• ·MFM proxy statement mailed to shareholders as of December 11, 2025, in early February 2026.

02-04-2026

CISO Global, Inc. filed a 10-K/A on April 02, 2026, amending Item 10 to update its directors, executive officers, and corporate governance details. Key personnel include CEO and Director David G. Jemmett (59), CFO Debra L. Smith (55), and directors Andrew K. McCain (63), Phillip Balatsos (48), Mohsen (Michael) Khorassani (60), and Andrew Hancox (55). Kyle J. Young (43) resigned as Interim Chief Operating Officer, with his resignation tendered on December 22, 2025, and effective January 2, 2026.

• ·Phillip Balatsos, Mohsen (Michael) Khorassani, and Andrew Hancox serve on the Audit, Compensation, and Governance and Nominating Committees.
• ·Kyle J. Young tendered resignation on December 22, 2025.

02-04-2026

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) appointed Peter Anastasiou as Chief Operating Officer, effective with his resignation from the Board of Directors. The company also appointed Troy Ignelzi as a director to fill the vacancy and nominated Geno J. Germano for election at the 2026 Annual Meeting of Shareholders, while Antonio Gracias will not stand for re-election. These changes are positioned to support the company's next phase of growth and long-term value creation.

• ·Announcement date: April 2, 2026
• ·Harmony headquartered in Plymouth Meeting, Pa.
• ·2026 Annual Meeting of Shareholders for director elections

02-04-2026

Commercial Vehicle Group (CVGI) completed a sale-leaseback transaction for its Vonore, Tennessee manufacturing facility, generating $16 million in proceeds used to prepay a portion of its existing term loan and reduce leverage. The company will lease back the property for a 20-year term with an initial annual base rent of approximately $1.4 million, anticipating no operational disruptions. CVG reaffirmed its full-year 2026 outlook previously issued on March 10, 2026.

• ·Manufacturing facility location: Vonore, Tennessee
• ·Announcement date: April 2, 2026
• ·Prior outlook issuance date: March 10, 2026

02-04-2026

Selig Zises resigned from all director and committee positions at Esquire Financial Holdings, Inc., Esquire Bank, National Association, and their affiliates, effective immediately on March 31, 2026, after over 17 years of service. The resignation is due to personal health and related disability concerns. It is explicitly stated that the resignation does not result from any disagreement with the Company or the Bank.

• ·Filing submitted on April 02, 2026 under Items 5.02 and 9.01

02-04-2026

Beacon Financial Corporation (BBT) has filed a DEFA14A notice for its 2026 Annual Stockholder Meeting on May 13, 2026, at 11:00 AM EDT, held virtually at www.virtualshareholdermeeting.com/BBT2026. Shareholders can vote on the election of 16 director nominees, ratification of KPMG LLP as independent auditors for the year ending December 31, 2026, and a non-binding advisory vote on named executive officer compensation, with voting deadline May 12, 2026. Proxy materials, including the Notice, Proxy Statement, CEO Letter, and Form 10-K, are available online at www.ProxyVote.com or by request before April 29, 2026.

• ·Filing date: April 02, 2026
• ·Vote by: May 12, 2026 11:59 P.M. ET
• ·Material request deadline: April 29, 2026

02-04-2026

ENB Financial Corp's DEF 14A proxy statement, filed April 2, 2026, solicits votes for the May 5, 2026 annual shareholder meeting to elect three Class C directors (Rachel G. Bitner, Joshua E. Hoffman, Susan Y. Nicholas) and ratify S.R. Snodgrass, P.C. as independent auditor for the year ending December 31, 2026. Compensation actually paid to the Principal Executive Officer (PEO) increased 3% YoY to $604,319 in 2025 from $588,486 in 2024. However, average compensation actually paid to other Named Executive Officers (NEOs) declined sharply 39% YoY to $334,503 in 2025 from $544,179 in 2024.

• ·Annual shareholder meeting scheduled for May 5, 2026 at 1:00 p.m. ET, Ephrata National Bank, Ephrata, PA.
• ·Record date for voting: March 10, 2026.
• ·PEO fair value adjustments in 2025: +$4,982 (to vesting date); Other NEOs: +$2,778 (prior to current unvested), -$336 (to vesting date).

02-04-2026

Lipocine Inc. (LPCN) filed an 8-K on April 2, 2026, under Items 8.01 and 9.01, announcing the issuance of a press release with topline safety and efficacy results for LPCN 1154 in patients with postpartum depression. The press release is furnished as Exhibit 99.1. No specific quantitative details on the results were disclosed in the filing itself.

• ·Filing reference: Commission File No. 001-36357
• ·Securities: Common Stock, par value $0.0001 per share, traded as LPCN on The NASDAQ Stock Market LLC
• ·Principal executive offices: 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108

02-04-2026

McAlister, Sweet & Associates, Inc. filed its 13F-HR on April 2, 2026, for the quarter ended March 31, 2026, disclosing total holdings of $160567854 across 32 positions, all with sole voting and investment discretion. The portfolio is diversified with heavy emphasis on broad market ETFs like SPDR S&P 500 ETF ($48017204 or 30% of total), Invesco QQQ Trust ($11489285), and Schwab U.S. Dividend Equity ETF ($10193600), alongside individual stocks such as Apple Inc. ($9355128) and Amazon.com Inc. ($5999217). No changes from prior periods are detailed in this snapshot filing.

• ·All 32 holdings reported with sole voting and sole investment discretion (SH SOLE).
• ·Firm address: 19500 St. Hwy. 249, Suite 345, Houston, TX 77070.
• ·No other managers reported (value 0).

02-04-2026

Crumly & Associates Inc. filed its 13F-HR report for the quarter ended March 31, 2026, disclosing 200 equity positions with a total market value of $475948297. Key holdings include Distillate US Fund ($20788511), Distillate International Fund ($19755282), Bitwise Bitcoin ETF ($9430759), Vanguard S&P 500 ETF ($7246656), and Apple Inc. ($5609610). No additions, reductions, or other changes were reported across any positions.

• ·Report period end date: 20260331
• ·Filing date: 20260402
• ·All holdings reported under sole discretionary voting authority
• ·No reported changes (additions, deletions, or share adjustments) from prior quarter

02-04-2026

MJT & Associates Financial Advisory Group, Inc. filed its 13F-HR report disclosing total holdings valued at $136,216,419 across 442 positions as of March 31, 2026. The portfolio is heavily weighted toward ETFs, with the largest position in Schwab U.S. Dividend Equity ETF at $23,214,345, followed by iShares 0-5 Year TIPS Bond ETF ($7,946,217) and iShares Core MSCI International Developed Markets ETF ($5,262,962). All reported holdings are sole discretionary with no shared or other manager positions indicated.

• ·Report filed April 2, 2026, for period ending March 31, 2026.
• ·Firm based in Montevideo, MN, with EIN 270373486.
• ·All holdings reported as SOLE discretionary (no changes, shared, or other categories listed).

02-04-2026

On March 31, 2026, Milestone Scientific Inc. entered into an Amendment to its Amended and Restated Memorandum of Understanding dated January 13, 2026, with Innovest S.p.A., holder of certain rights with respect to BP4 S.r.l., which owns 11.31% of the Company's outstanding common stock. The Amendment revises the definitions of 'Qualified Offering' and 'Other Locked-Up Parties' to facilitate an offering by the Company. No financial terms or impacts were disclosed.

• ·Amendment attached as Exhibit 10.1
• ·Filing signed by Eric Hines on April 2, 2026

02-04-2026

BV Financial, Inc., holding company for BayVanguard Bank, has filed a definitive proxy statement for its 2026 Annual Meeting of Stockholders on May 7, 2026, at 3:00 p.m. local time in Essex, Maryland. Key items include the election of three directors for three-year terms and ratification of Crowe LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The record date is March 13, 2026, with 8,790,568 shares of common stock outstanding; record holders owning more than 10% are limited in voting excess shares.

• ·Annual Report on Form 10-K for fiscal year ended December 31, 2025 available at https://www.edocumentview.com/BVFL.
• ·Proxy materials mailed beginning April 2, 2026.
• ·Internet/telephone voting deadline: 11:59 p.m. ET on May 6, 2026.
• ·ESOP and 401(k) Plan voting instructions deadline: April 30, 2026.
• ·Quorum requires majority of outstanding shares; directors elected by plurality, auditor ratification by majority of votes cast.

02-04-2026

CBL subsidiaries entered into a Credit Agreement dated March 27, 2026, for a single advance term loan of $176,080,000 to finance the acquisition of Mortgaged Properties including East Towne Mall, Mayfaire Town Center, Pearland Town Center, and Southaven Towne Center. The loan is provided by Beal Bank USA as Initial Lender, with CLMG Corp. as Administrative Agent, and is guaranteed by CBL Outparcel Holdco, LLC, CBL Outparcel Holdco Parent, LLC, CBL & Associates Holdco II, LLC, and CBL & Associates Limited Partnership. The new loan is cross-defaulted with an existing Affiliate Loan originally in the amount of $360,000,000.

• ·Agreement Closing Date: March 27, 2026
• ·SEC 8-K Filing Date: April 02, 2026
• ·Loan secured by Liens on Mortgaged Properties and cross-defaulted with Affiliate Loan amended concurrently via First Amendment dated March 27, 2026

02-04-2026

On April 1, 2026, Justin Earl resigned from the Board of Directors of Bioscience Health Innovations, Inc., effective immediately, with no disagreements on operations, policies, or practices. The Board appointed Daniel Schmidt, the Company's Chief Technology Officer since inception, as a director to fill the vacancy. Mr. Schmidt brings 26 years of experience in therapeutic medical devices including Radio Frequency, Stem Cells, Laser, Ultrasound Technologies, Non-Surgical Skin Tightening, and Fat Reduction.

• ·Company is an emerging growth company and has elected not to use the extended transition period for new financial accounting standards.
• ·No securities registered pursuant to Section 12(b) of the Act.
• ·Former name: NOWTRANSIT INC.

02-04-2026

On April 1, 2026, Kroll Bond Rating Agency (KBRA) affirmed long-term credit ratings for Univest Financial Corporation and Univest Bank and Trust Co. with a Stable Outlook. For the Corporation, ratings include senior unsecured debt at BBB+, subordinated debt at BBB, and short-term debt at K2. For the Bank, ratings include deposit and senior unsecured debt at A-, subordinated debt at BBB+, and short-term deposit and debt at K2.